36 related articles for article (PubMed ID: 18427281)
1. Exenatide reduces atrial fibrillation susceptibility by inhibiting hKv1.5 and hNav1.5 channels.
Zhou Q; Hao G; Xie W; Chen B; Lu W; Wang G; Zhong R; Chen J; Ye J; Shen J; Cao P
J Biol Chem; 2024 May; 300(5):107294. PubMed ID: 38636665
[TBL] [Abstract][Full Text] [Related]
2. Putative binding sites for arachidonic acid on the human cardiac Kv 1.5 channel.
Bai JY; Ding WG; Kojima A; Seto T; Matsuura H
Br J Pharmacol; 2015 Nov; 172(22):5281-92. PubMed ID: 26292661
[TBL] [Abstract][Full Text] [Related]
3. The Experimental TASK-1 Potassium Channel Inhibitor A293 Can Be Employed for Rhythm Control of Persistent Atrial Fibrillation in a Translational Large Animal Model.
Wiedmann F; Beyersdorf C; Zhou XB; Kraft M; Foerster KI; El-Battrawy I; Lang S; Borggrefe M; Haefeli WE; Frey N; Schmidt C
Front Physiol; 2020; 11():629421. PubMed ID: 33551849
[TBL] [Abstract][Full Text] [Related]
4. TASK-1 channel blockade by AVE1231 increases vasocontractile responses and BP in 1- to 2-week-old but not adult rats.
Shvetsova AA; Gaynullina DK; Schmidt N; Bugert P; Lukoshkova EV; Tarasova OS; Schubert R
Br J Pharmacol; 2020 Nov; 177(22):5148-5162. PubMed ID: 32860629
[TBL] [Abstract][Full Text] [Related]
5. Differential Modulation of
Martinez-Mateu L; Saiz J; Aromolaran AS
Front Physiol; 2019; 10():1212. PubMed ID: 31607952
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Beat-to-Beat Variations of P-Waves Morphologies in AF Patients During Sinus Rhythm: A Scoping Review of the Atrial Simulation Studies.
Filos D; Tachmatzidis D; Maglaveras N; Vassilikos V; Chouvarda I
Front Physiol; 2019; 10():742. PubMed ID: 31275161
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and Drug Development in Atrial Fibrillation.
Calvo D; Filgueiras-Rama D; Jalife J
Pharmacol Rev; 2018 Jul; 70(3):505-525. PubMed ID: 29921647
[TBL] [Abstract][Full Text] [Related]
8. Substance P Depolarizes Lamprey Spinal Cord Neurons by Inhibiting Background Potassium Channels.
Thörn Pérez C; Hill RH; Grillner S
PLoS One; 2015; 10(7):e0133136. PubMed ID: 26197458
[TBL] [Abstract][Full Text] [Related]
9. Voltage-gated potassium channels as therapeutic targets.
Wulff H; Castle NA; Pardo LA
Nat Rev Drug Discov; 2009 Dec; 8(12):982-1001. PubMed ID: 19949402
[TBL] [Abstract][Full Text] [Related]
10. New pharmacological strategies for the treatment of atrial fibrillation.
Burashnikov A; Antzelevitch C
Ann Noninvasive Electrocardiol; 2009 Jul; 14(3):290-300. PubMed ID: 19614642
[TBL] [Abstract][Full Text] [Related]
11. New antiarrhythmic drugs for the treatment of atrial fibrillation.
Schmitt J; Ehrlich JR; Hohnloser SH
Herz; 2008 Dec; 33(8):562-7. PubMed ID: 19137246
[TBL] [Abstract][Full Text] [Related]
12. Can inhibition of IKur promote atrial fibrillation?
Burashnikov A; Antzelevitch C
Heart Rhythm; 2008 Sep; 5(9):1304-9. PubMed ID: 18774108
[TBL] [Abstract][Full Text] [Related]
13. Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations.
Caballero R; Gómez R; Núñez L; Moreno I; Tamargo J; Delpón E
Cardiovasc Res; 2004 Dec; 64(3):457-66. PubMed ID: 15537499
[TBL] [Abstract][Full Text] [Related]
14. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
15. Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase.
Gong YZ; Ding WG; Wu J; Tsuji K; Horie M; Matsuura H
Eur J Pharmacol; 2008 Dec; 600(1-3):18-25. PubMed ID: 18930721
[TBL] [Abstract][Full Text] [Related]
16. Inward rectifier potassium currents as a target for atrial fibrillation therapy.
Ehrlich JR
J Cardiovasc Pharmacol; 2008 Aug; 52(2):129-35. PubMed ID: 18670367
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation.
McBride BF
J Clin Pharmacol; 2009 Mar; 49(3):258-67. PubMed ID: 19246727
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.
Ehrlich JR; Ocholla H; Ziemek D; Rütten H; Hohnloser SH; Gögelein H
J Cardiovasc Pharmacol; 2008 Apr; 51(4):380-7. PubMed ID: 18427281
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
